Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): A drug use investigation

Journal of Infection and Chemotherapy

Volumn 20, Issue 11, 2014, Pages 689-695

  Komeda, Takuji ^a   Ishii, Shingo ^a   Itoh, Yumiko ^a   Ariyasu, Yasuyuki ^a   Sanekata, Masaki ^a   Yoshikawa, Takayoshi ^a   Shimada, Jingoro ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Influenza; Peramivir; Post marketing surveillance; Safety profile

Indexed keywords

PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; SIALIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; HUMAN; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SINGLE DRUG DOSE; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; POSTMARKETING SURVEILLANCE; TIME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYCLOPENTANES; DIARRHEA; FEMALE; GUANIDINES; HUMANS; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; NAUSEA; NEURAMINIDASE; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; VOMITING; YOUNG ADULT;

EID: 84908246191     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.07.006     Document Type: Article

References (14)

1. H. Yu, Q. Liao, Y. Yuan, L. Zhou, N. Xiang, and Y. Huai Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China BMJ 341 2010 c4779
2. S.G. Yang, B. Cao, L.R. Liang, X.L. Li, Y.H. Xiao, and Z.X. Cao Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus PLoS One 7 2012 e29652
3. A. Rodriguez, E. Diaz, I. Martin-Loeches, A. Sandiumenge, L. Canadell, and J.J. Diaz Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A J Antimicrob Chemother 66 2011 1140 1149
4. J.K. Louie, S. Yang, M. Acosta, C. Yen, M.C. Samuel, and R. Schechter Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09 Clin Infect Dis 55 2012 1198 1204
5. S. Jain, L. Kamimoto, A.M. Bramley, A.M. Schmitz, S.R. Benoit, and J. Louie Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 N Engl J Med 361 2009 1935 1944
6. R. Libster, J. Bugna, S. Coviello, D.R. Hijano, M. Dunaiewsky, and N. Reynoso Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina N Engl J Med 362 2010 45 55
7. S. Bantia, C.D. Parker, S.L. Ananth, L.L. Horn, K. Andries, and P. Chand Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir Antimicrob Agents Chemother 45 2001 1162 1167
8. S. Bantia, C.S. Arnold, C.D. Parker, R. Upshaw, and P. Chand Anti-influenza virus activity of peramivir in mice with single intramuscular injection Antivir Res 69 2006 39 45
9. L.V. Gubareva, R.G. Webster, and F.G. Hayden Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants Antimicrob Agents Chemother 45 2001 3403 3408
10. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009 MMWR Morb Mortal Wkly Rep 58 2009 433 435
11. F. Hayden Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 2009 S3 S13
12. S. Kohno, H. Kida, M. Mizuguchi, and J. Shimada Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection Antimicrob Agents Chemother 54 2010 4568 4574
13. S. Kohno, H. Kida, M. Mizuguchi, N. Hirotsu, T. Ishida, and J. Kadota Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients Antimicrob Agents Chemother 55 2011 2803 2812
14. S. Kohno, M.Y. Yen, H.J. Cheong, N. Hirotsu, T. Ishida, and J. Kadota Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection Antimicrob Agents Chemother 55 2011 5267 5276